Recent Company News

• 09:53 AM ET Dec 24, 2025
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (94 total)

• 08:36 AM ET Dec 24, 2025
  

  S&P Global Ratings Upgrades Teva to 'BB+' Amid Strong Execution of Pivot to Growth Strategy; Moody's Ratings Agency Revises Outlook to Positive

• 10:02 AM ET Dec 23, 2025
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (170 total)

• 10:06 AM ET Dec 22, 2025
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (182 total)

• 03:40 AM ET Dec 19, 2025
  

  Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea(R)

• 03:36 AM ET Dec 19, 2025
  

  Alvotech, Teva reach settlement, license agreement with Regeneron for AVT06 in US; terms undisclosed ($4.73, 0.00)

• 04:42 PM ET Dec 18, 2025
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 10:52 AM ET Dec 18, 2025
  

  Truist 2026 Biotech outlook

• 07:09 AM ET Dec 17, 2025
  

  Sagimet Biosciences and TAPI announce global license agreement for innovative forms of resmetirom API for Sagimet's fixed dose combination program ($6.05, 0.00)

• 04:29 PM ET Dec 12, 2025
  

  Teva to Host Conference Call to Discuss Fourth Quarter 2025 Financial Results at 8 a.m. ET on January 28, 2026